New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
17:02 EDTAIV, CP, HME, AGNPershing Square gives quarterly update on stakes
NEW STAKES: None. INCREASED STAKES: Allergan (AGN). DECREASED STAKES: Canadian Pacific Railway (CP). LIQUIDATED STAKES: Apartment Investment and Management (AIV), and Home Properties (HME).
News For AGN;CP;AIV;HME From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 22, 2015
09:00 EDTHMEUDR, Inc. to acquire six apartment communities in exchange for OP units
Subscribe for More Information
08:57 EDTHMEHome Properties expects merger transaction to close during Q4
The board of Home Properties has unanimously approved the merger agreement and has recommended approval of the Home Properties Merger by the Home Properties stockholders and of the Home Properties OP Merger by the Home Properties OP unitholders. The transaction is expected to close during the fourth quarter of 2015, subject to the approval of the Home Properties Merger by the Home Properties stockholders and the approval of the Home Properties OP Merger by the Home Properties OP unitholders. The definitive agreement contains a "go shop" provision under which Home Properties may solicit alternative proposals from third parties during the next 30 calendar days on customary terms and conditions for transactions of this nature. The Home Properties Board, with the assistance of its advisors, has the right to actively solicit acquisition proposals during this period. There can be no assurances that this process will result in any alternative transaction.
08:56 EDTHMEUDR Inc. to acquire certain Home Properties assets in connection with merger
Concurrently with the execution of the merger agreement with Lone Star Funds, Home Properties (HME) has entered into an agreement to contribute a portfolio of up to six properties containing as many as 3,246 units to UDR (UDR) in exchange for a combination of cash and newly issued units. In connection with this transaction, existing holders of partnership units of Home Properties will have the opportunity to elect to exchange their Home Properties OP Units for 2.15 newly issued UDR DownREIT Units for each Home Properties OP Unit held, plus $3.01 in cash from Lone Star Funds. Unitholders who elect to receive UDR DownREIT Units in the OP Merger will also receive new tax protection for a period of 10 years from the closing date, regardless of the current tax protection status of their Home Properties OP Units. Prior to the Home Properties Merger and pursuant to the Merger Agreement, Lone Star Funds will acquire all of the Home Properties OP Units that are not owned by Home Properties and have not been exchanged as described above pursuant to a merger of Home Properties OP with a wholly owned subsidiary of Lone Star Funds (the "OP Merger"). In connection with the OP Merger, holders of Home Properties OP Units who have not exchanged their Home Properties OP Units as described above will receive $75.23 per unit in cash upon the closing of the OP Merger.
08:54 EDTHMEHome Properties agrees to be acquired by Lone Star Funds for $75.23 per share
Subscribe for More Information
June 19, 2015
16:24 EDTAGNStocks end week higher after Fed reassures on gradual pace of rate increases
Subscribe for More Information
June 17, 2015
17:19 EDTAGNOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
12:23 EDTAGNOn The Fly: Top stock stories at midday
Subscribe for More Information
10:44 EDTAGNSynergy a potential takeover target after constipation drug data
The shares of Synergy Pharmaceuticals (SGYP) are rallying after the company announced that its chronic constipation treatment had met its primary endpoint in a Phase 3 clinical trial. Research firm Canaccord has previously identified Synergy as a potential takeover target and a Bloomberg report said the company had hired advisers to explor a potential sale. WHAT'S NEW: Synergy reported this morning that the 3 mg and 6 mg versions of its anti-constipation drug, plecanatide, had met their primary endpoint in a Phase III trial. Specifically, a statistically significant percentage of patients taking both versions of the drugs responded favorably, based on criteria that the FDA uses to determine approval of chronic constipation treatments, the company stated. Plecanatide was safe and well tolerated at both dose, and the results were positive, the company reported. "These results strengthen our belief that plecanatide has the potential to not only effectively treat constipation but with a durability and tolerability profile that is ideal for chronic use," said Synergy CEO Gary Jacob. "We look forward to the results of our second pivotal trial in the coming weeks," he added. WHAT'S NOTABLE: In a note to investors on May 22, Canaccord analyst Corey Davis initiated coverage of Synergy with a Buy rating. There is "a high likelihood" that data from the company's four Phase III trials due to be conducted over the next year will be positive and the company would be an attractive takeover target if its Phase III data is positive, Jacobs wrote. The analyst placed an $11 price target on the shares. Meanwhile, in March, Bloomberg reported that Synergy was talking to advisers about potentially selling the company after its competitor, Salix Pharmaceuticals, had agreed to be acquired by Valeant Pharmaceuticals (VRX). After the company reported the trial results today, its CEO told Bloomberg that "all options are on the table." IRONWOOD: The shares of Ironwood (IRWD), whose Linzess drug also treats chronic constipation, are falling today following Synergy's data readout. Canaccord's Davis had said that the diarrhea rate of patients taking Synergy's plecanatide had to come in at 10% or lower for the drug to achieve "best differentiation" versus Linzess. Patients taking the 3 mg dose of plecanatide had a diarrhea rate of 5.5%, while 5.9% of those taking the 6 mg dose experienced diarrhea, Synergy reported. Linzess is co-marketed by Ironwood and Forest Pharmaceuticals, a unit of Allergan (AGN). PRICE ACTION: In morning trading, Synergy surged 45% to $6.74, while Ironwood slid fractionally to $12.16.
09:25 EDTAGNIronwood slips after Synergy announces data on constipation drug
Shares of Ironwood (IRWD) are lower in pre-market trading after Synergy Pharmaceuticals (SGYP) announced top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses in adult patients with chronic idiopathic constipation. Plecanatide was safe and well tolerated at both doses, Synergy said, noting that the most common adverse event was diarrhea, which occurred in 5.9% of patients in 3.0 mg and 5.5% of patients in 6.0 mg dose groups. Ironwood’s competing Linzess drug had a 16% diarrhea rate for CIC patients, according to its FDA label. Linzess is co-marketed by Ironwood and Forest Pharmaceuticals, a unit of Allergan (AGN). Ironwood shares are down 45c, or 3.7%, to $11.75 in pre-market trading.
09:16 EDTAGNAllergan buyout of KYTHERA boosts aesthetics portfolio, says BMO Capital
BMO Capital says Allergan's (AGN) buyout of KYTHERA (KYTH) builds out the company's aesthetics portfolio. KYTHERA's double chin treatment Kybella "could be a game changer in contouring," and there is no company better suited to make that happen than Allergan, BMO tells investors in a research note. The firm keeps an Outperform rating on Allergan with a $378 price target.
07:44 EDTAGNKYTHERA volatility low into Allergan acquiring for approximately $2.1B
Subscribe for More Information
07:21 EDTAGNGeneric ADHD drugs still sold despite FDA non-equivalance finding, NYT reports
The FDA announced last November that two generic versions of Johnson & Johnson's (JNJ) Concerta ADHD drug, one made by Mallinckrodt (MNK) and the other by UCB, could no longer be considered the equivalent of the branded drug after tests and analyses suggested that their effectiveness began to wear off much more quickly, but the drugs are still being sold despite an FDA mandated deadline having passed for the companies to either prove the drugs were equivalent or remove them from the market, said The New York Times. The report noted a third generic product, sold by Actavis (AGN), was found to be equivalent to the branded Concerta. Reference Link
07:15 EDTAGNAllergan to host conference call
Conference call to discuss a definitive agreement to acquire KYTHERA Biopharmaceuticals-(KYTH) will be held at 8:30 am on June 17. Webcast Link
07:04 EDTAGNAllergan to acquire KYTHERA for $75 per share, or $2.1B
Subscribe for More Information
07:03 EDTAGNAllergan agrees to acquire KYTHERA for $75 per share or approximately $2.1B
Subscribe for More Information
07:03 EDTAGNAllergan agrees to acquire KYTHERA for $75 per share or approximately $2.1B
Subscribe for More Information
07:02 EDTAGNAllergan to acquire KYTHERA for $75 per share, or $2.1B
June 16, 2015
18:14 EDTCPCanadian Pacific plans to purchase up to 853K shares through going private deals
Canadian Pacific announced that it intends to purchase for cancellation up to 853,000 of its common shares pursuant to private agreements to be entered into between CP and three arm's-length third-party sellers. Purchases will be made in accordance with three issuer bid exemption orders issued by the Ontario Securities Commission each dated June 16, and pursuant to the Orders, may be made in several transactions prior to March 17, 2016. The price CP will pay for its common shares purchased by way of private agreements will be at a discount to the prevailing market price of CP common shares on the Toronto Stock Exchange at the time of purchase. Purchases made by CP will be counted towards CP's normal course issuer bid announced on March 16, 2015 for up to 9.14M CP common shares and will not exceed, in aggregate, one third of the maximum number of common shares CP may purchase under the Bid, being 3.05M common shares.
07:41 EDTCPRail sector risk/reward attractive, but patience required, says UBS
Subscribe for More Information
05:45 EDTAGNAllergan, Richter announce FDA has extended review period for cariprazine
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use